Endocrinology

The landmark global policy recognizes obesity as chronic disease requiring lifelong care, warns of inequitable access and proposes 3-pillar strategy targeting prevention, screening, treatment.

Dorr says symptoms can begin 10 years before cylces cease and explains why the hormonal feast and famine of perimenopause can go unrecognized.

GLORY-2 participants showed continuous weight loss through 60 weeks with no plateau; mazdutide also improved multiple cardiometabolic markers.

FDA approves Dexcom Smart Basal, a groundbreaking CGM-integrated insulin dosing optimizer, enhancing diabetes management for adults with Type 2 diabetes.

A new study reveals that the Preventive Health Inventory enhances diabetes and hypertension management among veterans without increasing hospitalizations.

In the phase 2 clinical trial, tradipitant, an oral neurokinin-1 receptor antagonist, was dosed twice daily among adults with obesity and treated with semaglutide.

Nearly 40% of perimenopausal women report misdiagnosis as clinicians treat for anxiety and depression without addressing underlying hormonal imbalance.

Recognize Cushing syndrome in primary care: key clinical clusters, first-line screening tests (DST, salivary cortisol, UFC), and when to refer to endocrinology.

Adults with diabetes often face obstacles to optimal disease management in the workplace. Use this checklist in the clinic to help them navigate the barriers.

Trump announces deals with Eli Lilly and Novo Nordisk slashing GLP-1 prices to as low as $150/month, expanding Medicare coverage starting mid-2026.

Oral semaglutide 25 mg improved glucose control and CV risk factors across weight loss categories in OASIS 4 post hoc analysis presented at ObesityWeek 2025.

Global survey data highlight persistent stigma and self-management barriers for adults with diabetes in the workplace, with implications for clinical care.

These 42 factors that affect blood glucose are in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.

Your daily dose of the clinical news you may have missed.

The real-world study of 200,000+ adults found no GI safety differences among 3 GLP-1 drugs for T2D, however SGLT-2 inhibitors are safer for motility issues.

Use of GLP-1 receptor agonists for weight loss has more than doubled since early 2024 while 7.6 million fewer US adults qualify as obese in 2025.

The model predicts 14 different T2D complications that can develop over ~15 years, and models how the disease progresses by predicting change in risk factors over time.

The phase 3 DREAMS-3 trial is the fist phase 3 head-to-head comparison of a GLP-1/glucagon dual receptor agonist against semaglutide in diabetes treatment.

After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.

In a subanalysis of the SELECT trial, semaglutide was associated with reduction in MACE across weight and waist circumference categories, independent of body fat.

TMS 2025: Early natural menopause significantly raises the risk of metabolic syndrome, highlighting the need for proactive health interventions in at-risk women.

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

Your daily dose of the clinical news you may have missed.

GLP-1 RAs liraglutide, semaglutide, and dulaglutide showed similar kidney and cardiovascular outcomes more than 20,000 US veterans with type 2 diabetes.

Topline phase 3 data shows oral GLP-1 cuts HbA1c by 2.1% when added to basal insulin, nearly triple placebo's effect in patients poorly controlled on current therapy.